March 16 / 2021

KABS LABORATORIES ANNOUNCE A SIGNIFICANT SUPPORT FROM THE STRATEGIC INNOVATION FUND

We are pleased to announce a significant support from the Strategic Innovation Fund which allows KABS to accelerate its activities in the field of bioprocesses and the development of biological drugs at St-Hubert and Val-des-Sources. We would like to thank the Government of Canada, the Municipality of Val-des-Sources, and the Sherbrooke Office of Investissement Quebec for their continuous and diligent attention to our projects.

“Canada’s biomanufacturing sector is rich in knowledge and expertise. By investing in domestic biomanufacturing facilities and equipment, such as KABS Laboratories, Novocol and Immune Biosolutions, we are investing in made-in-Canada solutions to fight COVID-19 while retaining and developing the expertise necessary to help us secure vaccine and therapy supply chains here at home. Our government is committed to rebuilding Canada’s biomanufacturing sector, focusing on both short-term strategic solutions and a long-term vision.”

– The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry

May 13 / 2020

Exvastat receives prestigious Innovative Medicines Initiative grant to fund clinical study of imatinib in the treatment of COVID-19-associated ARDS.

Under the award, Exvastat will collaborate with Vrije Universitat, Amsterdam Medical Center, KABS (Canada) and Simbec-Orion to produce a reformulated version of the drug and test it in critically ill COVID-19 patients.